just the facts, I totally agree with you but unfortunately most people here and on the Yahoo board are day-traders which means that they don't really invest in the stock, they day trade it. Many don't even hold their position over a weekend. Getting approval on Bio-T-Gel will be welcoming news but to me the biggest news we could get is and update from BioSante indicating that they are still COMMITTED to seeing LibiGel through to NDA submittal! That could mean that they will continue as planned and submit the NDA by September after the June safety trial data is released OR worse case scenario they are required to initiate another 6-month efficacy trial. In either case, this news will be HUGE and it should pump no less than a buck back into the stock price.
Then there's the current, ongoing LibiGel extension trial. I expect that they will have results of this trial by sometime late February (maybe early March). Plus we know that BioSante is currently looking at data from subset analysis, hopefully from a subset of HSDD women only. In fact, the subset analysis could possibly be the agreed to ITT protocol population, who knows. Let's hope that the subset data analysis shows striking efficacy differences between LibiGel and placebo because if it does I suppose that BioSante will submit the NDA with that data as proof of efficacy.
The cancer vaccine portfolio is potentially worth a lot as well but as you know, BioSante has really been focusing on LibiGel and for good reason i.e. the clinical trials are governed by an SPA and so the expectations are high. LibiGel would represent some needed funding that could then be used to help fund the vaccine program.
The good thing about Simes is that he prefers to fund operations by methods other than by selling stock and as a shareholder I appreciate it.
Approval of Bio-T-gel should hopefully be a no-brainer. The FDA has a great interest in approving Bio-T-gel because it will help slow down physicians from issuing off-label prescriptions. The stock price may or may not drop a little after approval of T-gel but after that it will start to recover again, imo.
News 
Market Data 
Discover 
